33 Result(s)

Article

Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression

Ad-ISF35 is an adenovirus (Ad) vector that encodes a mouse–human chimeric CD154. Ad-ISF35 induces activation of chronic lymphocytic leukemia (CLL) cells converting them into CLL cells capable of promoting immu...

J Melo-Cardenas, M Urquiza, T J Kipps, J E Castro in Cancer Gene Therapy (2012)

Article

Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors

Intensive research is devoted to unravel the neurobiological mechanisms mediating adult hippocampal neurogenesis, its regulation by antidepressants, and its behavioral consequences. Macrophage migration inhibi...

L Conboy, E Varea, J E Castro, H Sakouhi-Ouertatani, T Calandra… in Molecular Psychiatry (2011)

Article

A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154

Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell–T cell interactions and enhances the sensitivity of CLL cells to clearance by ad...

W G Wierda, J E Castro, R Aguillon, D Sampath, A Jalayer, J McMannis… in Leukemia (2010)

Article

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia

We observed that high-dose methylprednisolone (HDMP) and rituximab was well tolerated and had promising activity when used in combination to treat patients with fludarabine-refractory chronic lymphocytic leuke...

J E Castro, D F James, J D Sandoval-Sus, S Jain, J Bole, L Rassenti, T J Kipps in Leukemia (2009)

Article

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

We examined the clinical response of fludarabine-refractory CLL patients treated with high-dose methylprednisolone (HDMP) and rituximab. Fourteen patients were treated with three cycles of rituximab (375 mg/m² we...

J E Castro, J D Sandoval-Sus, J Bole, L Rassenti, T J Kipps in Leukemia (2008)

Article

Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference

We compared antisense phosphorothioate oligonucleotides (PS-ODN) that target BCL-2 such as Genasense^® (G3139-PS), with other PS-ODN or phosphodiester-ODN (PO-ODN) in their relative capacity to induce apoptosis of...

J E Castro, C E Prada, R A Aguillon, S Kitada, T Fukuda, M Motta, C Wu… in Leukemia (2006)

Article

Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation

We investigated the apoptosis gene expression profile of chronic lymphocytic leukemia (CLL) cells in relation to (1) normal peripheral and tonsillar B-cell subsets, (2) IgV_H mutation status, and (3) effects of cy...

W J M Mackus, A P Kater, A Grummels, L M Evers, B Hooijbrink, M H H Kramer… in Leukemia (2005)

Chapter

Renal transplantation

The concept of replacing diseased and worn-out organs is a problem that has fascinated the minds of clinicians, scientists and philosophers for many years. It is exemplified by the chimera of Greek mythology; ...

J. E. Castro in The Treatment of Renal Failure (1981)

Article

Immune-complex disease in mice and humans given C. parvum

The present studies in mice and cancer-bearing patients, treated with C. parvum (CP) immunotherapy, were to determine the effects of CP on the production of immune complexes (IC) and associated disease. Using the...

H D Mitcheson, J Uff, B A Pussell, M Brill, J E Castro in British Journal of Cancer (1980)

Article

Single versus multiple human-equivalent doses of C. parvum in mice: neutralization of the anti-metastatic effect

The murine dose of i.v. C. parvum (466 microgram) was compared with a single, low, human-equivalent dose of 70 microgram and with repeated weekly low doses. All treatments increased the antibody titre against C. ...

H D Mitcheson, T E Sadler, J E Castro in British Journal of Cancer (1980)

Article

Mechanisms of C. parvum-induced coagulopathy in mice

I.v. injection of Corynebacterium parvum (CP) into C57BL and BALB/c mice caused profound coagulation changes, featuring thrombocytopenia, decreased fibrinogen, increased fibrin/fibrinogen degradation products,...

H D Mitcheson, P Hilgard, A McCraw, J E Castro in British Journal of Cancer (1980)

Chapter

Reticuloendothelial System Function in Cancer Patients Treated with C. Parvum

The anti-tumour effect of C. parvum (C.p.) in rodents is generally regarded as being mediated by non-specific activation of macrophages (reviewed by Milas and Scott, 1978). The phagocytic index in mice is incr...

H. D. Mitcheson, Adele Nicolas, N. Bowley, J. E. Castro in Metastasis (1980)

Chapter

Acute Changes in Calcitonin Levels in Lung Cancer Patients Treated with C. Parvum: Do These Reflect in Vivo Killing of Tumour Cells?

Calcitonin (CT) is a useful biochemical marker for monitoring progress of patients with bronchial carcinoma (McKenzie et al, 1977; Silva et al, 1979). There is considerable evidence that such calcitonin is pro...

H. D. Mitcheson, C. J. Hillyard, I. MacIntyre, J. E. Castro in Metastasis (1980)

Article

Effects of amputation and Corynebacterium parvum on tumour metastases in mice

The effects of operation (lower-limb amputation) on the growth of the Lewis lung tumour and its metastases were studied. The role of C. parvum in counteracting these effects was investigated. Anaesthesia alone or...

J G Mosley, T E Sadler, J E Castro in British Journal of Cancer (1978)

Article

Hormonal environment of immunosuppressed mice

G Williams, R Ghanadian, A S Papadopoulos, J E Castro in British Journal of Cancer (1978)

Chapter

Experimental non-specific immunotherapy

Following the demonstration by Foley¹ in 1953, and Prehn and Main² in 1957, that experimental tumours exhibit specific antigens, one approach to cancer therapy has been to modify the host immune response. Immunot...

Tessa E. Sadler, J. E. Castro in Immunological Aspects of Cancer (1978)